Health Monitor Network acquires D+R Lathian
Expanding its digital HCP engagement and omnichannel offering
Health Monitor Network has acquired D+R Lathian, an omnichannel healthcare marketing company specialising in digital HCP engagement and owner of the MyDrugRep.com platform. The transaction expands Health Monitor’s capabilities in point-of-care marketing, with a stated focus on more measurable and integrated engagement solutions for pharmaceutical, biotech and medical device brands.
Health Monitor’s leadership has emphasised the deal as a further step in its growth strategy, allowing its pharma clients to access broader HCP activation and omnichannel execution. The company will combine its proprietary physician office network – reported as over 250,000 offices and more than 450,000 HCPs – with D+R Lathian’s digital marketing and audience analytics tools.
David Paragamian, Health Monitor Network CEO, said the acquisition is intended to offer “the broadest omnichannel platform in point of care,” noting complementary strengths in both HCP activation and integrated channel reach. Reide Rosen, Co-Founding Partner at D+R Lathian, commented that the combined organisation aims to “create more connected brand experiences and deliver stronger results for our clients across the healthcare ecosystem.”
The point-of-care sector continues to grow as pharma marketers look to engage HCPs in more measurable, data-driven environments. Digital activation and omnichannel orchestration are in demand as brand teams seek to break down silos between patient and professional media touchpoints. Health Monitor’s proprietary content studio remains central, generating branded educational assets designed for real-world physician-patient dialogue.
solli’s Final Thoughts
This acquisition highlights the continued shift towards more integrated, data-driven point-of-care engagement. While point of care has long been valued for its proximity to clinical decision-making, the industry has often struggled to measure campaign impact with the same level of accuracy as other digital channels.
What makes this deal notable is the focus on combining real-world physician office reach with stronger digital engagement and analytics capabilities. For pharma marketers, the opportunity is not just broader omnichannel engagement, but potentially more measurable and accountable point-of-care campaigns.
The industry is still evolving in this area, and it remains to be seen how effectively these models can deliver consistent measurement at scale. However, the direction is clear: brands increasingly want connected engagement strategies that can demonstrate real performance across both HCP and patient touchpoints.
Most Popular Content
